News Article | April 27, 2017
"We are pleased to recognize Catherine Mott's impact on the angel investment community and her achievements on behalf of so many start-ups. Her contributions have helped to vastly expand the reach, resources, quality, and diversity of angel investors and the startup economy nationwide," said John Huston, Chairman Emeritus of ACA and Founder and Chairman Emeritus of Ohio TechAngel Funds. As of December 2016, BlueTree Allied Angels has invested more than $42 million in 55 startup companies, and BlueTree Venture Fund has $10 million under management. Mott serves on the boards of Anglr, Figure 8, Peptilogics, Imprint, and Westmoreland Advanced Materials. She holds a portfolio monitor seat with Cryothermics, Instream Media, Lube Holdings, Zone 2 Surgical, Thorley (4Moms), Cisse, and Rinovum Women's Health. Mott represents America's angel community to the Securities and Exchange Commission by serving as a member of the SEC Advisory Committee on Small and Emerging Companies. She is a past chairman of both ACA and the Angel Resource Institute (ARI), helping both organizations to grow and better serve the angel community. She also has been an instructor for a variety of ARI courses all over the country and beyond. "I'm excited about Catherine's selection for the Hans Severiens Award," said Marianne Hudson, ACA's executive director. "Not only was she a stellar leader for ACA, but she helped more women become angels. She was one of the few who had the courage to 'invite herself' to angel investing more than ten years ago, and ensure many more broke through the doors, in a thoughtful and professional way." "I am thrilled to receive this honor. This award is a reflection on those many individuals who helped me when I became an angel investor, and who provided guidance for managing outcomes and nurturing entrepreneurial companies on their way to success," said Mott. ACA selected Magnetic Insight as winner of the 2017 Luis Villalobos Award for ingenuity, creativity, and innovation among startups. Magnetic Insight was selected based on competitive differentiation and progress toward bringing a product, service, or solution to market. Based in Alameda, CA, Magnetic Insight has introduced Magnetic Particle Imaging (MPI), the first new diagnostic imaging technique since the introduction of CT, MRI, and PET over 30 years ago. MPI gives clinicians and scientists a precise and sensitive new tool for early diagnosis, for patient monitoring, and for research. Magnetic Insight has launched a research imaging scanner and is now developing the first clinical system. The company beat out finalists DesignMedix, Inc., of Portland, OR, and Peloton Technology, Mountain View, CA, for the award. A detailed 2017 ACA Summit agenda is available here. About the Angel Capital Association (ACA) ACA is the professional association of angel investors across North America and offers education, best practices, public policy advocacy, and significant benefits and resources to its membership of more than 13,000 accredited investors, who invest individually or through its 250 angel groups, accredited platforms, and family offices. For more information, visit: www.angelcapitalassociation.org or at @ACAAngelCapital; #ACAAngelSummit. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/angel-capital-association-honors-pittsburgh-based-angel-catherine-mott-and-innovative-company-magnetic-insight-300447662.html
Andrews S.,Portland State University |
Burgess S.J.,Portland State University |
Burgess S.J.,DesignMedix |
Skaalrud D.,Portland State University |
And 4 more authors.
Journal of Medicinal Chemistry | Year: 2010
We have shown that "reversed chloroquine molecules" constructed from chloroquine-like and resistance "reversal-agent"-like cores can be powerful drugs against malaria (J. Med. Chem. 2006, 49, 5623-5625). Several reversed chloroquines are now presented that probe parameters governing the activities against chloroquine-resistant and chloroquine-sensitive malaria strains. The design is tolerant to linker and reversal agent changes, but a piperazinyl group adjacent to the quinoline, at least for the group of compounds studied here, may be detrimental. ©2009 American Chemical Society.
Burgess S.J.,Portland State University |
Burgess S.J.,DesignMedix |
Kelly J.X.,Portland State University |
Kelly J.X.,Portland Veterans Affairs Medical Center |
And 9 more authors.
Journal of Medicinal Chemistry | Year: 2010
We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the Structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine. © 2010 American Chemical Society.
News Article | July 18, 2014
DesignMedix, Inc., a Portland, Oregon-based biotech startup, has closed a $1.5m second round of angel funding. Investors include Portland Seed Fund, as well as members of Bellingham Angels, Oregon Angel Fund, Seraph Angel Network, Willamette Angel Conference, Keiretsu Angel Forum and Tacoma Angel Network. The company intends to use the funds for further development of a pipeline of drugs that combat drug resistance, including malaria drugs and new anti-bacterial drugs. Founded in 2008 and led by Dr. Sandra Shotwell, president and COO, DesignMedix develops drugs to overcome drug resistance. Its initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has exclusive rights to four issued patents relating to drug candidates for malaria drugs. The company’s lab and office are housed in the PSU Business Accelerator. DesignMedix was recently awarded a $3m grant from the National Institutes of Health to support preclinical development of its malaria drug.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase I | Award Amount: 353.90K | Year: 2016
DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence and severity of cervical and prostate cancers Only two drugs are FDA approved for the treatment of trichomoniasis the nitro heterocyclic compounds metronidazole Mz and tinidazole Oral dosing leads to clinical and microbiological cure in the majority of cases but treatment failures occur in a significant fraction of patients up to with reports of increasing resistance in the U S High oral Mz or tinidazole doses in combination with topical treatment of the same drug s have been used with success for Mz refractory vaginal trichomoniasis whereas topical Mz treatment alone is only modestly effective and so is not recommended While topical treatment is possible in principle as shown in murine models and would be attractive because low systemic absorption is likely to reduce systemic adverse effects compared to oral formulations current drugs are not sufficiently potent for this preferred administration route Given the prevalence of trichomoniasis its association with multiple disease outcomes and the increase in drug resistant strains as well as the potential for more resistance development of new antimicrobials against trichomoniasis is an urgent need Our preliminary studies of andgt newly synthesized nitro compounds provide compelling evidence that novel nitro drugs can be developed with marked improvements in potency and the ability to completely overcome existing drug resistance Such andquot next generationandquot nitro drugs have the distinct advantage that this antimicrobial class contrary to any other compound class is already established to be effective and safe against trichomoniasis The increased potency of our novel compounds should allow development of a topical treatment Therefore the project has the overall objective to develop a new lead nitro compound for the topical treatment of Mz sensitive and Mz resistant trichomoniasis Based on our prior data we have selected several of the most promising structural domains and will now perform focused structural explorations within these domains The new derivatives will be tested for activity and potency against Mz sensitive and Mz resistant T vaginalis in vitro for cytotoxicity and genotoxicity in mammalian cells in vitro and for efficacy in a murine model of vaginal trichomoniasis in vivo The comprehensive bioactivity and toxicity data to be generated in this project will be used to select two non toxic compounds with the best combination of high potency and ability to overcome resistance in vitro and good efficacy in vivo as lead and back up for subsequent preclinical development of a novel high potency compound for the topical treatment of trichomoniasis in phase II of the project PUBLIC HEALTH RELEVANCE Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection in the U S and worldwide Only two drugs metronidazole and tinidazole are currently FDA approved for the oral treatment of trichomoniasis but treatment failures and resistance occur in up to of cases and no topical treatment is effective without concurrent systemic therapy Supported by extensive preliminary work on potential new drugs the proposed project will develop the most potent candidates as novel high potency lead compounds for the topical treatment of trichomoniasis
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 600.00K | Year: 2011
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. A small set of carefully-selectedcandidates will be advanced through preclinical testing, leading to the selection of a single drug for a pre-Investigational New Drug meeting with the Food and Drug Administration. With guidance from the Food and Drug Administration, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys in phase II of this work. The overall goal will be completion of preclinical studies leading to approval of the Investigative New Drug (IND) application for a drug to be used in a Phase-1 human clinical trial. PUBLIC HEALTH RELEVANCE: Malaria is a disease that infects about half a billion people annually, and kills nearly one million, most of whom are children or pregnant women. The impact of malaria is increasing, partly because the parasite that causes malaria has evolved into strains that are resistant to the best current drugs for treating the disease. This project involves preclinical evaluation of novel drugs designed to circumvent this resistance, paving the way toward approval for human clinical trials. The drug candidates show promising results in early studies, and are designed to be inexpensive as well as safe for all target groups, including pregnant women and children.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 102.61K | Year: 2012
DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths occur in sub-Saharan Africa among the more vulnerable groups, such as children and pregnant women. In addition to the fatalities, malaria imparts a huge economic burden on the endemic countries, many of which are also the world's poorest. In some of the worst affected countries as much as 40% of their total health expenditure is spent on malaria, as current drug treatments are expensive. Although there are several approved antimalarial drugs, the malaria parasite asa great ability to develop resistance, to such an extent that drug resistance has been identified to every current therapy. This drug resistance can be sufficiently strong as to render the drug almost ineffective, as is the case with chloroquine, once the'gold star' treatment for malaria. DesignMedix has developed a novel set of antimalarial compounds, the lead of which is currently undergoing preclinical trials. The goal of this proposal is to optimize the synthesis of the lead compound, developing the method from a research laboratory scale, to one ready for plant-scale production. The aim is to improve the yields and reduce production costs in an effort to keep the overall cost of the drug as low as possible and therefore affordable to those who need it. PUBLIC HEALTH RELEVANCE: Malaria is a parasitic disease which kills around 800 thousand people each year, mainly children and pregnant women in sub-Saharan Africa. The parasite has a great ability to develop drug resistance, such that currentlythere are strains resistant to ever approved drug, so there is a continuing need for new therapies that are less expensive than current drugs. This work is to develop a novel antimalarial drug, from research laboratory scale to a method suitable for fullscale production.